The expression of elafin and its implication in the inflammatory and keratinizing disorders of the skin

Hyeok Kim Chong Hyeok Kim, Nam Kim Soo Nam Kim, Hae Jun Song

Research output: Contribution to journalArticle

Abstract

Background: Elafin is a serine proteinase inhibitor first discovered in keratinocytes from psoriatic epidermis. The molecular structure of elafin contains two different functional domains; one for the proteinase inhibitor, which is directed against elastase and proteinase-3, and the other for transglutaminase substrate. As this unique structural characteristic implies, elafin would be expected to have two distinct biologic functions in tissues. But, the roles and biological features of elafin have not been extensively studied in the skin. Objectives: This study was designed to demonstrate the immunohistochemical localization of elafin in inflammatory and keratinizing skin disorders, and to elucidate its biological functions. Materials and methods: The pre-elafin sequence was amplified by PCR using a human epidermal cDNA library and expression construct which was ligated into an expression vector. Then, the expressed proelafin sequence was purified and injected intradermally into rabbits to raise a polyclonal antibody. The skin biopsy samples of various skin diseases and normal controls were used for immunohistochemical staining to detect elafim expression. Results: 1) Expression of elafin was observed in infected epidermis, and is believed to be involved in the defense mechanism of the skin. 2) In dermal and subcutaneous inflammatory diseases, epidermal elafin expression was influenced by the location of the inflammation. 3) Elafin was expressed in bullous dermatoses accompanied by acantholysis or spongiosis of epidermal cells. 4) Expression of elafin was upregulated in papulosquamous skin diseases which was characterized by epidermal hyperplasia and abnormal differentiation. 5) Elafin was expressed in keratinizing skin diseases that was accompanied by abnormal differentiation of epidermal cells. 6) Expression of elafin was demonstrated in skin tumors that showed proliferation of suprabasal cells. The intensity of expression is not related to the degree of malignancy, but to the degree of differentiation of tumor cells. Conclusion: Induction of elafin expression may play an important role in protecting the skin components against tissue damage. Elafin expression is related to the abnormal proliferation and differentiation of suprabasal cells. This means that elafin may be used as a marker of these conditions.

Original languageEnglish
Pages (from-to)1603-1614
Number of pages12
JournalKorean Journal of Dermatology
Volume38
Issue number12
Publication statusPublished - 2000 Dec 1

Fingerprint

Elafin
Skin
Cell Differentiation
Skin Diseases
Epidermis
Papulosquamous Skin Diseases
Acantholysis
Vesiculobullous Skin Diseases
Myeloblastin
Neoplasms

Keywords

  • Elafin
  • Immunohistochemistry
  • Skin diseases

ASJC Scopus subject areas

  • Dermatology

Cite this

The expression of elafin and its implication in the inflammatory and keratinizing disorders of the skin. / Chong Hyeok Kim, Hyeok Kim; Soo Nam Kim, Nam Kim; Song, Hae Jun.

In: Korean Journal of Dermatology, Vol. 38, No. 12, 01.12.2000, p. 1603-1614.

Research output: Contribution to journalArticle

Chong Hyeok Kim, Hyeok Kim ; Soo Nam Kim, Nam Kim ; Song, Hae Jun. / The expression of elafin and its implication in the inflammatory and keratinizing disorders of the skin. In: Korean Journal of Dermatology. 2000 ; Vol. 38, No. 12. pp. 1603-1614.
@article{086c2fcac160425aa7f87105fe49d2bf,
title = "The expression of elafin and its implication in the inflammatory and keratinizing disorders of the skin",
abstract = "Background: Elafin is a serine proteinase inhibitor first discovered in keratinocytes from psoriatic epidermis. The molecular structure of elafin contains two different functional domains; one for the proteinase inhibitor, which is directed against elastase and proteinase-3, and the other for transglutaminase substrate. As this unique structural characteristic implies, elafin would be expected to have two distinct biologic functions in tissues. But, the roles and biological features of elafin have not been extensively studied in the skin. Objectives: This study was designed to demonstrate the immunohistochemical localization of elafin in inflammatory and keratinizing skin disorders, and to elucidate its biological functions. Materials and methods: The pre-elafin sequence was amplified by PCR using a human epidermal cDNA library and expression construct which was ligated into an expression vector. Then, the expressed proelafin sequence was purified and injected intradermally into rabbits to raise a polyclonal antibody. The skin biopsy samples of various skin diseases and normal controls were used for immunohistochemical staining to detect elafim expression. Results: 1) Expression of elafin was observed in infected epidermis, and is believed to be involved in the defense mechanism of the skin. 2) In dermal and subcutaneous inflammatory diseases, epidermal elafin expression was influenced by the location of the inflammation. 3) Elafin was expressed in bullous dermatoses accompanied by acantholysis or spongiosis of epidermal cells. 4) Expression of elafin was upregulated in papulosquamous skin diseases which was characterized by epidermal hyperplasia and abnormal differentiation. 5) Elafin was expressed in keratinizing skin diseases that was accompanied by abnormal differentiation of epidermal cells. 6) Expression of elafin was demonstrated in skin tumors that showed proliferation of suprabasal cells. The intensity of expression is not related to the degree of malignancy, but to the degree of differentiation of tumor cells. Conclusion: Induction of elafin expression may play an important role in protecting the skin components against tissue damage. Elafin expression is related to the abnormal proliferation and differentiation of suprabasal cells. This means that elafin may be used as a marker of these conditions.",
keywords = "Elafin, Immunohistochemistry, Skin diseases",
author = "{Chong Hyeok Kim}, {Hyeok Kim} and {Soo Nam Kim}, {Nam Kim} and Song, {Hae Jun}",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "38",
pages = "1603--1614",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "12",

}

TY - JOUR

T1 - The expression of elafin and its implication in the inflammatory and keratinizing disorders of the skin

AU - Chong Hyeok Kim, Hyeok Kim

AU - Soo Nam Kim, Nam Kim

AU - Song, Hae Jun

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Background: Elafin is a serine proteinase inhibitor first discovered in keratinocytes from psoriatic epidermis. The molecular structure of elafin contains two different functional domains; one for the proteinase inhibitor, which is directed against elastase and proteinase-3, and the other for transglutaminase substrate. As this unique structural characteristic implies, elafin would be expected to have two distinct biologic functions in tissues. But, the roles and biological features of elafin have not been extensively studied in the skin. Objectives: This study was designed to demonstrate the immunohistochemical localization of elafin in inflammatory and keratinizing skin disorders, and to elucidate its biological functions. Materials and methods: The pre-elafin sequence was amplified by PCR using a human epidermal cDNA library and expression construct which was ligated into an expression vector. Then, the expressed proelafin sequence was purified and injected intradermally into rabbits to raise a polyclonal antibody. The skin biopsy samples of various skin diseases and normal controls were used for immunohistochemical staining to detect elafim expression. Results: 1) Expression of elafin was observed in infected epidermis, and is believed to be involved in the defense mechanism of the skin. 2) In dermal and subcutaneous inflammatory diseases, epidermal elafin expression was influenced by the location of the inflammation. 3) Elafin was expressed in bullous dermatoses accompanied by acantholysis or spongiosis of epidermal cells. 4) Expression of elafin was upregulated in papulosquamous skin diseases which was characterized by epidermal hyperplasia and abnormal differentiation. 5) Elafin was expressed in keratinizing skin diseases that was accompanied by abnormal differentiation of epidermal cells. 6) Expression of elafin was demonstrated in skin tumors that showed proliferation of suprabasal cells. The intensity of expression is not related to the degree of malignancy, but to the degree of differentiation of tumor cells. Conclusion: Induction of elafin expression may play an important role in protecting the skin components against tissue damage. Elafin expression is related to the abnormal proliferation and differentiation of suprabasal cells. This means that elafin may be used as a marker of these conditions.

AB - Background: Elafin is a serine proteinase inhibitor first discovered in keratinocytes from psoriatic epidermis. The molecular structure of elafin contains two different functional domains; one for the proteinase inhibitor, which is directed against elastase and proteinase-3, and the other for transglutaminase substrate. As this unique structural characteristic implies, elafin would be expected to have two distinct biologic functions in tissues. But, the roles and biological features of elafin have not been extensively studied in the skin. Objectives: This study was designed to demonstrate the immunohistochemical localization of elafin in inflammatory and keratinizing skin disorders, and to elucidate its biological functions. Materials and methods: The pre-elafin sequence was amplified by PCR using a human epidermal cDNA library and expression construct which was ligated into an expression vector. Then, the expressed proelafin sequence was purified and injected intradermally into rabbits to raise a polyclonal antibody. The skin biopsy samples of various skin diseases and normal controls were used for immunohistochemical staining to detect elafim expression. Results: 1) Expression of elafin was observed in infected epidermis, and is believed to be involved in the defense mechanism of the skin. 2) In dermal and subcutaneous inflammatory diseases, epidermal elafin expression was influenced by the location of the inflammation. 3) Elafin was expressed in bullous dermatoses accompanied by acantholysis or spongiosis of epidermal cells. 4) Expression of elafin was upregulated in papulosquamous skin diseases which was characterized by epidermal hyperplasia and abnormal differentiation. 5) Elafin was expressed in keratinizing skin diseases that was accompanied by abnormal differentiation of epidermal cells. 6) Expression of elafin was demonstrated in skin tumors that showed proliferation of suprabasal cells. The intensity of expression is not related to the degree of malignancy, but to the degree of differentiation of tumor cells. Conclusion: Induction of elafin expression may play an important role in protecting the skin components against tissue damage. Elafin expression is related to the abnormal proliferation and differentiation of suprabasal cells. This means that elafin may be used as a marker of these conditions.

KW - Elafin

KW - Immunohistochemistry

KW - Skin diseases

UR - http://www.scopus.com/inward/record.url?scp=0034511321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034511321&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1603

EP - 1614

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 12

ER -